Crossject Société Anonyme (EPA:ALCJ)

Market Cap	109.44M
Revenue (ttm)	4.07M
Net Income (ttm)	-11.26M
Shares Out	52.74M
EPS (ttm)	-0.22
PE Ratio	n/a
Forward PE	3.92
Dividend	n/a
Ex-Dividend Date	n/a

Volume	39,596
Average Volume	163,022
Open	2.065
Previous Close	2.075
Day's Range	2.015 - 2.065
52-Week Range	0.720 - 2.695
Beta	0.57
RSI	40.86
Earnings Date	Dec 24, 2025

About Crossject Société Anonyme

Crossject Société Anonyme develops needle-free injection systems in France. The company develops ZENEO, needle-free, pre-filled, single-use auto-injector. Its product pipeline includes Midazolam for epileptic seizure; Naloxone for opioid overdose; Terbutaline for the treatment of severe asthma crisis; Epinephrine for anaphylactic shock; and Sumatriptan for the treatment of migraine and cluster headaches, as well as Hydrocortisone for acute adrenal crisis and Methotrexate for the treatment of rheumatoid arthritis. In addition, the company is dev...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 2001
• Employees: 102
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALCJ

Financial Performance

In 2024, Crossject Société Anonyme's revenue was 4.12 million, an increase of 6.28% compared to the previous year's 3.87 million. Losses were -12.80 million, 48.1% more than in 2023.